BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3884084)

  • 1. A randomized controlled trial of prophylactic cytotoxic chemotherapy in potentially curable breast cancer.
    Gough MH; Durrant KR; Giraud-Saunders AM; Paine CH; McPherson K; Vessey MP
    Br J Surg; 1985 Mar; 72(3):182-5. PubMed ID: 3884084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant use of cytotoxic chemotherapy to destroy micrometastasis in breast cancer after local control therapy--current status.
    Carter SK
    Clin Exp Metastasis; 1983; 1(1):1-15. PubMed ID: 6399695
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
    Carter SK
    Postgrad Med; 1985 Jan; 77(1):75-7, 80-3. PubMed ID: 3880891
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant systemic therapy in primary breast cancer.
    Mouridsen HT; Palshof T
    Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
    Henderson IC
    J Clin Oncol; 1985 Feb; 3(2):140-3. PubMed ID: 3881560
    [No Abstract]   [Full Text] [Related]  

  • 7. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy in stage II breast cancer: a brief overview of the NSABP clinical trials.
    Wolmark N; Fisher B
    World J Surg; 1985 Oct; 9(5):699-706. PubMed ID: 2856855
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant systemic therapy for resectable breast cancer.
    Bonadonna G; Valagussa P
    J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of breast cancer: current views and results.
    Bonadonna G; Valagussa P
    Int J Radiat Oncol Biol Phys; 1983 Mar; 9(3):279-97. PubMed ID: 6341335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial.
    Fisher B; Brown A; Wolmark N; Redmond C; Wickerham DL; Wittliff J; Dimitrov N; Legault-Poisson S; Schipper H; Prager D
    Ann Intern Med; 1987 May; 106(5):649-54. PubMed ID: 3551710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.
    Mackay IR; Goodyear MD; Riglar C; Penschow J; Whittingham S; Russell IS; Kitchen PR; Collins JP
    Cancer; 1984 Jun; 53(12):2619-27. PubMed ID: 6609758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable factors in the adjuvant therapy of breast cancer.
    Carpenter JT; Maddox WA; Laws HL; Wirtschafter DD; Soong SJ
    Cancer; 1982 Jul; 50(1):18-23. PubMed ID: 7044517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.